会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
    • 具有检查点激酶1抑制活性的吲哚基 - 吡啶酮衍生物
    • US08916591B2
    • 2014-12-23
    • US12812791
    • 2009-01-20
    • Stephen StokesNicolas FoloppeAndrea FiumanaMartin DrysdaleSimon BedfordPaul Webb
    • Stephen StokesNicolas FoloppeAndrea FiumanaMartin DrysdaleSimon BedfordPaul Webb
    • A61K31/4439C07D401/14
    • C07D401/14A61K31/4439A61K31/4545A61K31/496A61K31/5377C07D413/14
    • Compounds of formula (I) have checkpoint kinase 1 (CHK1) inhibitory activity: wherein R1, R2, R5 and R6 are independently selected from hydrogen, hydroxy, methyl, trifluoromethyl, hydroxymethyl, methoxy, trifluoromethoxy, methylamino and dimethylamino; R3, and R4 are independently selected from hydrogen, hydroxy, C1-C3 alkyl, fluoro-(C1-C3)-alkyl, hydroxy-(C1C3)-alkyl, C1-C3 alkoxy, fluoro-(C1-C3)-alkoxy, hydroxy-(C1-C3)-alkoxy, -AIk-N(R11)—R12, -0-AIk-N(R11)—R12, —C(═O)OH, carboxy-(C1-C3)-alkyl, or —C(═O)—NH—R13; AIk is a straight or branched chain divalent C1-C6 alkylene radical; R7 and R8 are independently selected from hydrogen, hydroxy, or C1-C3 alkoxy; X is a straight chain divalent C1-C3 alkylene radical, optionally substituted on one or more carbons by R9 and/or R10; W is selected from —C(═O)—N(—R16)— or —N(—R17)—C(═O)—; Y is hydrogen, C1-C3 alkyl, C1-C3 alkoxy, or halo; and Q is selected from optionally substituted phenyl, optionally substituted cyclohexyl, or an optionally substituted 6-membered monocyclic heteroaryl ring.
    • 式(I)化合物具有检测点激酶1(CHK1)抑制活性:其中R1,R2,R5和R6独立地选自氢,羟基,甲基,三氟甲基,羟甲基,甲氧基,三氟甲氧基,甲基氨基和二甲基氨基; R 3和R 4独立地选自氢,羟基,C 1 -C 3烷基,氟 - (C 1 -C 3) - 烷基,羟基 - (C 1 -C 3) - 烷基,C 1 -C 3烷氧基,氟 - (C 1 -C 3) - 烷氧基, 羟基 - (C1-C3) - 烷氧基,-Ik-N(R11)-R12,-O-Alk-N(R11)-R12,-C(= O)OH,羧基 - (C1-C3) - 烷基, 或-C(= O)-NH-R 13; Alk是直链或支链二价C1-C6亚烷基; R 7和R 8独立地选自氢,羟基或C 1 -C 3烷氧基; X是直链的二价C1-C3亚烷基,任选地被一个或多个碳上被R9和/或R10取代; W选自-C(= O)-N(-R 16) - 或-N(-R 17)-C(= O) - ; Y是氢,C 1 -C 3烷基,C 1 -C 3烷氧基或卤素; 并且Q选自任选取代的苯基,任选取代的环己基或任选取代的6元单环杂芳基环。
    • 2. 发明申请
    • INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY
    • 具有检测点激酶1的吲哚基 - 吡啶酮衍生物1抑制活性
    • US20110021498A1
    • 2011-01-27
    • US12812791
    • 2009-01-20
    • Stephen StokesNicolas FoloppeAndrea FiumanaMartin DrysdaleSimon BedfordPaul Webb
    • Stephen StokesNicolas FoloppeAndrea FiumanaMartin DrysdaleSimon BedfordPaul Webb
    • A61K31/397A61P35/00A61P19/02C07D401/14A61K31/4439A61K31/444A61K31/4545C07D413/14A61K31/5377
    • C07D401/14A61K31/4439A61K31/4545A61K31/496A61K31/5377C07D413/14
    • Compounds of formula (I) have checkpoint kinase 1 (CHK1) inhibitory activity: wherein R1, R2, R5 and R6 are independently selected from hydrogen, hydroxy, methyl, trifluoromethyl, hydroxymethyl, methoxy, trifluoromethoxy, methylamino and dimethylamino; R3, and R4 are independently selected from hydrogen, hydroxy, C1-C3 alkyl, fluoro-(C1-C3)-alkyl, hydroxy-(C1C3)-alkyl, C1-C3 alkoxy, fluoro-(C1-C3)-alkoxy, hydroxy-(C1-C3)-alkoxy, -AIk-N(R11)—R12, -0-AIk-N(R11)—R12, —C(═O)OH, carboxy-(C1-C3)-alkyl, or —C(═O)—NH—R13; AIk is a straight or branched chain divalent C1-C6 alkylene radical; R7 and R8 are independently selected from hydrogen, hydroxy, or C1-C3 alkoxy; X is a straight chain divalent C1-C3 alkylene radical, optionally substituted on one or more carbons by R9 and/or R10; W is selected from —C(═O)—N(—R16)— or —N(—R17)—C(═O)—; Y is hydrogen, C1-C3 alkyl, C1-C3 alkoxy, or halo; and Q is selected from optionally substituted phenyl, optionally substituted cyclohexyl, or an optionally substituted 6-membered monocyclic heteroaryl ring.
    • 式(I)化合物具有检测点激酶1(CHK1)抑制活性:其中R1,R2,R5和R6独立地选自氢,羟基,甲基,三氟甲基,羟甲基,甲氧基,三氟甲氧基,甲基氨基和二甲基氨基; R 3和R 4独立地选自氢,羟基,C 1 -C 3烷基,氟 - (C 1 -C 3) - 烷基,羟基 - (C 1 -C 3) - 烷基,C 1 -C 3烷氧基,氟 - (C 1 -C 3) - 烷氧基, 羟基 - (C1-C3) - 烷氧基,-Ik-N(R11)-R12,-O-Alk-N(R11)-R12,-C(= O)OH,羧基 - (C1-C3) - 烷基, 或-C(= O)-NH-R 13; Alk是直链或支链二价C1-C6亚烷基; R 7和R 8独立地选自氢,羟基或C 1 -C 3烷氧基; X是直链的二价C1-C3亚烷基,任选地被一个或多个碳上被R9和/或R10取代; W选自-C(= O)-N(-R 16) - 或-N(-R 17)-C(= O) - ; Y是氢,C 1 -C 3烷基,C 1 -C 3烷氧基或卤素; 并且Q选自任选取代的苯基,任选取代的环己基或任选取代的6元单环杂芳基环。